At the 13th International Conference on Advanced Technology and Treatments for
Diabetes (ATTD) in Madrid, a key event for global scientist, leading healthcare
professionals and life science decision makers, Lifecare A/S (LIFE-ME) presented
a poster on its advances in the development of the Sencell Continuous Glucose
monitor.

The poster with the title “Miniaturization of an Osmotic Pressure Based
Injectable Glucose Sensor” highlighted the planned device evolution and the
accuracy of the employed 3D nanosensor technology measurement system. The data
shows that the Sencell technology probably employs the smallest MEMS based
pressure sensor in the world, with a reliable reproducibility of measurement
results and a pressure resolution, which should lead to a resolution of glucose
differences higher than CGM-devices currently on the market. The data presented
was well received by the scientific community.

Lifecare A/S (LIFE-ME) is developing an implantable sensor for continuous
glucose monitoring in the interstitial fluid. Proof of concept of the
proprietary osmotic pressure sensing technology has been successfully performed
in preclinical trials and the company is now continuing the development of a
sensor prototype suitable for first human clinical experiments. 

The poster is published at https://www.lifecare.no/scientific-poster.